Back to search results

Baricitinib for Long COVID Symptoms

This study is looking into whether a medication called baricitinib can help improve thinking skills and other symptoms in people with Long COVID. Long COVID can cause lasting problems like difficulty thinking, shortness of breath, and tiredness. Researchers want to see if baricitinib, compared to a placebo (an inactive pill that looks like the real medicine), can improve these issues, as well as physical function and quality of life. You may be able to join if you are 18 years or older and have Long COVID. The main way they will measure success is by looking at your thinking abilities after 6 months. The current status of this study is unclear, and it aims to enroll 550 participants.

Study design
This is a randomized, double-blind study, meaning participants are randomly assigned to receive either baricitinib or a placebo, and neither you nor your doctor will know which you are receiving. It plans to enroll 550 participants.
What's involved
You would take a pill by mouth once a day for 24 weeks. Your thinking abilities will be measured at Month 6.
Compensation
Not stated in the trial record.
Follow-up
Your thinking abilities will be measured at Month 6, which is the primary endpoint for this study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06631287

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Recruiting
PHASE3Ages 18+InterventionalTreatment
Wes Ely
~550 participants
Updated 2026-05-11 on ClinicalTrials.gov
What's tested:BaricitinibPlacebo

At a glance

Recruiting sites
17 of 17 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
CNS-Vital Signs Global Cognitive Index
Measured over Month 6

Conditions

Long COVID
Sars-CoV-2 Infection
Coronavirus Infections
COVID-19

Explore related trials

Post-Acute Sequelae of COVID-19

NCT06631287

Where you'd take part

This study runs at 17 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Brigham and Women's Hospital

    Boston, Massachusettsstudy coordinator listed

    Recruiting

  • Emory University

    Atlanta, Georgiastudy coordinator listed

    Recruiting

  • Illinois Research Network (ILLInet), University of Illinois Chicago

    Chicago, Illinoisstudy coordinator listed

    Recruiting

  • NYU Langone Health - Brooklyn

    Brooklyn, New Yorkstudy coordinator listed

    Recruiting

  • Swedish Medical Center

    Seattle, Washingtonstudy coordinator listed

    Recruiting

  • The MetroHealth System

    Cleveland, Ohiostudy coordinator listed

    Recruiting

  • University Hospitals Cleveland Case Western

    Cleveland, Ohiostudy coordinator listed

    Recruiting

  • University of Arizona

    Tucson, Arizonastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Wes Ely, M.D. · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center

Who to contact

Amanda Bistran-Hall
[email protected]
615-343-8010
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

OR- ii. At least one of the following symptoms: Cough, shortness of breath, or difficulty breathing.
OR- iii. Severe respiratory illness with at least one of the following: clinical or radiographic evidence of pneumonia or Acute Respiratory Distress Syndrome (ARDS).
AND- iv. No alternate more likely diagnosis 4. Clinical evidence of Long COVID, as confirmed by the clinician's assessment:

What this trial measures

  • CNS-Vital Signs Global Cognitive IndexMonth 6

    Objective neuropsychological function determined using the CNS-Vital Signs Global Cognitive Index between study arms at 6-months, adjusted for baseline. CNS-Vital Signs Global Cognitive Index subscale is an average score derived from the domain scores or a general assessment of the overall neurocognitive status of the participant. The scores range from less than 70 (very low) to above 110 (above average). A higher score means higher neurocognitive function and higher capacity.